Lehigh Valley Health Network, Allentown, PA
DeSales University, Center Valley, PA.
J Dr Nurs Pract. 2020 Jul 1;13(2):148-155. doi: 10.1891/JDNP-D-19-00059. Epub 2020 Jul 2.
Acute respiratory distress syndrome (ARDS) is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar capillary permeability, increased lung weight, and loss of aerated lung tissue (Fan, Brodie, & Slutsky, 2018). Primary treatment for ARDS is artificial mechanical ventilation (AMV) (Wu, Huang, Wu, Wang, & Lin, 2016). Given recent advances in technology, the use of veno-venous extracorporeal membrane oxygenation (VV-ECMO) to treat severe ARDS is growing rapidly (Combes et al., 2014).
This 49-month quantitative, retrospective inpatient EMR chart review compared if cannulation with VV-ECMO up to and including 48 hours of admission and diagnosis in adult patients 30 to 65 years of age diagnosed with ARDS, decreased duration on AMV, as compared to participants who were cannulated after 48 hours of admission and diagnosis with ARDS.
A total of 110 participants were identified as receiving VV-ECMO during the study timeframe. Of the 58 participants who met all inclusion criteria, 39 participants were cannulated for VV-ECMO within 48 hours of admission and diagnosis with ARDS, and 19 participants were cannulated with VV-ECMO after 48 hours of admission and diagnosis with ARDS.
Data collected identified no statistically significant ( < 0.579) difference in length of days on AMV between participant groups.
Further studies are needed to determine if earlier initiation of VV-ECMO in adult patients with ARDS decrease time on AMV.
Although the results related to length of time on AMV did not produce statistical significance, the decreased duration of AMV in the participants who were cannulated within 48 hours (21 days vs. 27 days) may support several benefits associated with this participant population including increased knowledge of healthcare providers, decreased lung injury, earlier discharge which decreases hospital and patient cost, ability for patients to communicate sooner, decreased risk of pulmonary infection, decreased length of stay, decreased cost, and improved patient and family satisfaction.
急性呼吸窘迫综合征(ARDS)的特征为急性、弥漫性、炎症性肺损伤,导致肺泡毛细血管通透性增加、肺重量增加以及肺泡充气组织丧失(Fan、Brodie 和 Slutsky,2018)。ARDS 的主要治疗方法为人工机械通气(AMV)(Wu、Huang、Wu、Wang 和 Lin,2016)。鉴于最近技术的进步,使用静脉-静脉体外膜肺氧合(VV-ECMO)治疗严重 ARDS 的应用迅速增长(Combes 等人,2014)。
这项为期 49 个月的定量、回顾性住院电子病历图表回顾比较了在诊断为 ARDS 后 30 至 65 岁的成人患者中,在入院和诊断后 48 小时内进行 VV-ECMO 置管与在入院和诊断后 48 小时后进行 VV-ECMO 置管的患者相比,是否减少了 AMV 的使用时间。
在研究期间共确定 110 名患者接受了 VV-ECMO 治疗。在符合所有纳入标准的 58 名患者中,39 名患者在诊断为 ARDS 后 48 小时内进行了 VV-ECMO 置管,19 名患者在诊断为 ARDS 后 48 小时后进行了 VV-ECMO 置管。
收集的数据表明,两组患者在 AMV 上的天数没有统计学上的显著差异(<0.579)。
需要进一步研究以确定在 ARDS 成人患者中更早开始 VV-ECMO 是否会减少 AMV 的使用时间。
尽管与 AMV 使用时间相关的结果未产生统计学意义,但在 48 小时内进行置管的患者中 AMV 的持续时间缩短(21 天与 27 天),这可能支持与该患者群体相关的一些益处,包括增加医疗保健提供者的知识、减少肺损伤、更早出院,从而降低医院和患者的成本、使患者更早进行沟通、降低肺部感染风险、缩短住院时间、降低成本以及提高患者和家属的满意度。